Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Ying Sun,1,2,* Beibei Chen,3,4,* Jisheng Li,3,* Ling Peng,5 Shuguang Li,3 Xuejun Yu,3 Li Li3 1Key Laboratory for Experimental Teratology of the Ministry of Education and Department of Pathology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University...
Main Authors: | Sun Y, Chen B, Li J, Peng L, Li S, Yu X, Li L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-09-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-analysis-of-the-efficacy-and-safety-of-a-novel-irreversible-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
by: Yin Y, et al.
Published: (2020-12-01) -
A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
by: Liu J, et al.
Published: (2021-09-01) -
Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report
by: Le-Tian Huang, et al.
Published: (2019-12-01) -
The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
by: Chaokun Wang, et al.
Published: (2021-05-01) -
Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
by: Li X, et al.
Published: (2021-07-01)